Several cancers underrepresented in clinical trials

Several cancers with a high burden of disease are not receiving the clinical trial investment they require. Four of the five cancers that result in the greatest burden of disease have relatively few clinical trials: lung, colorectal, prostate and pancreatic cancers.

The University of Sydney researchers found of 386 interventional cancer trials open to recruitment in Australia, breast cancer accounted for 62 trials. Yet only 24 trials were being conducted on lung cancer, despite it being responsible for the greatest burden of disease.

Read more at University of Sydney